To view this page ensure that Adobe Flash Player version 11.1.0 or greater is installed.

Breast Cancer Neoadjuvant Chemotherapeutic and Targeted Therapies for Early-stage, High-risk Breast Cancer Clement Chung 1 and Rosetta Lee 2 1. Oncology Clinical Pharmacist, Lyndon B Johnson General Hospital, Houston, Texas, US; 2. PGY1 Pharmacy Practice Resident, Ben Taub General Hospital, Houston, Texas, US Abstract Neoadjuvant or preoperative chemotherapy is the preferred treatment for locally advanced, inflammatory and early-stage high-risk breast cancers. Patients with locally advanced breast cancers are candidates for neoadjuvant therapy because their tumours are often not amenable to resection. On the other hand, patients are candidates for neoadjuvant chemotherapy if the breast-conserving surgery is not possible. At present, anthracycline- and taxane-based chemotherapy regimens remain as the cornerstone for neoadjuvant therapy in early breast cancer, but there is a clear need for effective therapies in high-risk, early-stage patients. A number of chemotherapeutic and targeted therapies have been evaluated in clinical trials with varying results. The US Food and Drug Administration (FDA) has recently approved pertuzumab in combination with trastuzumab and cytotoxic chemotherapy as a neoadjuvant therapy option for HER2-positive breast cancer. This article reviews the neoadjuvant chemotherapeutic and targeted therapies options for early-stage, high-risk breast cancer. Possible role of molecular subtyping in triple-negative breast cancer is also described. Keywords Neoadjuvant, triple-negative, locally advanced, inflammatory, breast cancer, HER2, molecular subtyping Disclosure: Clement Chung and Rosetta Lee have no conflicts of interest to declare. No funding was received for the publication of this article. Received: 20 March 2014 Accepted: 3 June 2014 Citation: European Oncology & Haematology, 2014;10(1):28–34 Correspondence: Clement Chung, Pharmacist, Lyndon B Johnson General Hospital, 5656 Kelley St, Houston, TX 77026, US. E: clement_t_chung@yahoo.com According to the World Health Organization (WHO), cancer-related mortalities reach 7.9 million worldwide each year. 1 Among women, breast cancer is one of the most common cancers globally. Despite advances in early detection and understanding on the molecular pathogenesis of breast cancer, approximately 30  % of patients with early-stage breast cancer experience recurrent disease. 2 Systemic treatment of breast cancer includes cytotoxic chemotherapy, endocrine (or hormonal) therapy and targeted therapy. These therapeutic agents are used in the adjuvant (post-surgical), neoadjuvant (pre-surgical) and metastatic settings. Neoadjuvant therapy (also referred to as preoperative, pre-surgical, induction or primary systemic therapy) is the systemic treatment of breast cancer in the preoperative setting with curative intent. It was first evaluated more than 30 years ago for the treatment of locally advanced, inflammatory (a subtype of locally advanced breast cancer) and inoperable breast cancers. 3 It is now increasingly used in patients with operable disease. 3 The primary objective of the neoadjuvant therapy is to improve surgical outcomes 3–5 in patients for whom a primary surgical approach is technically not feasible and in patients with operable breast cancer who desire breast conservation. Second, neoadjuvant therapy decreases the need for complete axillary lymph node dissection. 6–8 It also allows an early evaluation of the systemic therapy. Third, neoadjuvant therapy gives clinicians an opportunity to obtain tumour specimens prior to and during the preoperative treatment, thus enabling researchers to investigate emerging drug therapies and predictive biomarkers. 7,8 Recently, following the announcement by the US Food and Drug Administration (FDA) 9 that it 28 will consider neoadjuvant randomised trials for accelerated drug approval in early breast cancer, there has been a marked increase in clinical trials with novel agents in the neoadjuvant setting. This review focuses on the current and emerging neoadjuvant chemotherapies and targeted therapies for early-stage, high-risk 9 (defined as 20–25 % risk of recurrence or death at 5 years) breast cancer. Patient Selection Neoadjuvant chemotherapy is the preferred treatment for locally advanced and inflammatory breast cancer. According to the American Joint Committee on Cancer, 10 locally advanced breast cancer is a stage III disease. Clinically, locally advanced breast cancer includes tumours that are localised to the breast tissue without regional nodal involvement, and may also include tumour sizes greater than 5 cm in diameter, or tumours of any size with overlying oedema, chest-wall fixation, skin infiltration or inflammatory features. Among these forms of locally advanced breast cancer, only clinical stage IIIA (T0N2M0; T1-3N2M0) is considered surgically resectable; whereas clinical stage IIIB (T4N0-2M0) and stage IIIC (any TN3M0) are considered unresectable or inoperable. 11 Patients with locally advanced breast cancer IIIB-C are candidates for neoadjuvant therapy. Moreover, patients with high-risk, early-stage breast cancer (clinical stage I or II) are candidates for neoadjuvant therapy if breast-conserving surgery is not possible or if the tumour subtype is associated with a higher likelihood of response (e.g. human epidermal growth factor receptor type-2 [HER2]- positive or triple-negative [oestrogen receptor [OR]-negative, progesterone receptor [PR]-negative, HER2-negative), regardless of tumour size. 12,13 © TOUC H ME D IC AL ME D IA 2014